Dirk Tomsitz
7PUBLICATIONS
12CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Sep 04, 2025
Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma: results of a multicentre phase II trial.Sebastian Haferkamp, Bastian Schilling, Carola Berking
|Mar 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma.Dirk Tomsitz, Elisabeth Livingstone, Carmen Loquai
|Jul 14, 2023
Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study.Dirk Tomsitz, Theresa Ruf, Markus Heppt
|May 13, 2023
Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors.Dirk Tomsitz, Theresa Ruf, Sarah Zierold
|Jul 09, 2022
Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma.Dirk Tomsitz, Max Schlaak, Sarah Zierold
Pageof 2
Frequent Collaborators
3 joint publications
Bastian Schilling
1 joint publications
Knut Brockow
1 joint publications
Markus Heppt
1 joint publications
Ramon Staeger
1 joint publications
Egle Ramelyte
1 joint publications
Reinhard Dummer
1 joint publications
Jens T Siveke
1 joint publications
Cindy Franklin
1 joint publications
Ulrike Leiter
1 joint publications
Dirk Schadendorf
